Skip to main navigation Skip to search Skip to main content

Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus

  • Ghulam M. Ashraf*
  • , Nigel H. Greig
  • , Taqi A. Khan
  • , Iftekhar Hassan
  • , Shams Tabrez
  • , Shazi Shakil
  • , Ishfaq A. Sheikh
  • , Syed K. Zaidi
  • , Mohammad Akram
  • , Nasimudeen R. Jabir
  • , Chelaprom K. Firoz
  • , Aabgeena Naeem
  • , Ibrahim M. Alhazza
  • , Ghazi A. Damanhouri
  • , Mohammad A. Kamal
  • *Corresponding author for this work
  • King Fahd Medical Research Center (GMA)
  • King Abdulaziz University
  • National Institutes of Health
  • Sur College of Applied Sciences
  • King Saud University
  • Integral University
  • Aligarh Muslim University
  • Sur College of Applied Sciences

Research output: Contribution to journalArticlepeer-review

205 Citations (Scopus)

Abstract

In general, proteins can only execute their various biological functions when they are appropriately folded. Their amino acid sequence encodes the relevant information required for correct three-dimensional folding, with or without the assistance of chaperones. The challenge associated with understanding protein folding is currently one of the most important aspects of the biological sciences. Misfolded protein intermediates form large polymers of unwanted aggregates and are involved in the pathogenesis of many human diseases, including Alzheimer’s disease (AD) and Type 2 diabetes mellitus (T2DM). AD is one of the most prevalent neurological disorders and has worldwide impact; whereas T2DM is considered a metabolic disease that detrementally influences numerous organs, afflicts some 8% of the adult population, and shares many risk factors with AD. Research data indicates that there is a widespread conformational change in the proteins involved in AD and T2DM that form β-sheet like motifs. Although conformation of these β-sheets is common to many functional proteins, the transition from α -helix to β -sheet is a typical characteristic of amyloid deposits. Any abnormality in this transition results in protein aggregation and generation of insoluble fibrils. The abnormal and toxic proteins can interact with other native proteins and consequently catalyze their transition into the toxic state. Both AD and T2DM are prevalent in the aged population. AD is characterized by the accumulation of amyloid-β (Aβ) in brain, while T2DM is characterized by the deposition of islet amyloid polypeptide (IAPP, also known as amylin) within beta-cells of the pancreas. T2DM increases pathological angiogenesis and immature vascularisation. This also leads to chronic cerebral hypoperfusion, which results in dysfunction and degeneration of neuroglial cells. With an abundance of common mechanisms underpinning both disorders, a significant question that can be posed is whether T2DM leads to AD in aged individuals and the associations between other protein misfolding diseases.

Original languageEnglish
Pages (from-to)1280-1293
Number of pages14
JournalCNS and Neurological Disorders - Drug Targets
Volume13
Issue number7
DOIs
Publication statusPublished - 1 Mar 2014
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alzheimer’s disease
  • Amylin
  • Amyloid precursor protein
  • Amyloid-β
  • Islet amyloid polypeptide
  • Neurofibrillary tangles
  • Parkinson’s disease
  • Protein folding
  • Proteostasis
  • Tau
  • Tauopathy
  • Type 2 diabetes mellitus
  • α-synuclein

Fingerprint

Dive into the research topics of 'Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this